Arcutis to Report Fourth Quarter 2022 Financial Results and Participate in Upcoming Investor Conference
08 févr. 2023 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Quarterly investor conference call and webcast scheduled for Tuesday, February 28 at 4:30 p.m. ETArcutis management will also participate in the Cowen 43rd Annual Healthcare Conference in March ...
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
03 févr. 2023 16h10 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Feb. 03, 2023 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful...
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 déc. 2022 16h01 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful...
Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study Evaluating ARQ-255
05 déc. 2022 08h00 HE
|
Arcutis Biotherapeutics, Inc.
ARQ-255 is a topical janus kinase (JAK) inhibitor therapy specifically designed as a potential treatment for alopecia areataProprietary Deep Dermal Drug Delivery (4D) formulation designed to deliver...
Arcutis’ ZORYVE® (Roflumilast) Cream 0.3% Added to Express Scripts, Inc.® National Formularies in the United States
17 nov. 2022 08h00 HE
|
Arcutis Biotherapeutics, Inc.
ZORYVE is now on formulary for one of the top pharmacy benefit managers serving commercially insured patients, effective November 18, 2022ZORYVE is a once-daily non-steroidal cream and the first and...
Arcutis to Present at Upcoming Investor Conference
11 nov. 2022 08h00 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Nov. 11, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in...
Arcutis Announces Third Quarter 2022 Financial Results and Provides Business Update
08 nov. 2022 16h02 HE
|
Arcutis Biotherapeutics, Inc.
Launched ZORYVE® (roflumilast) cream 0.3% for the treatment of plaque psoriasis in adolescents and adults in mid-August, achieving net revenues of $0.7 million for the third quarterZORYVE now covered...
Arcutis to Report Third Quarter Financial Results
25 oct. 2022 16h05 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Oct. 25, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early-stage commercial company focused on developing meaningful innovations in...
Nationwide Seborrheic Dermatitis Survey Shows Burdensome and Lengthy Path to Diagnosis
21 oct. 2022 08h00 HE
|
Arcutis Biotherapeutics, Inc.
Findings presented at the annual Fall Clinical Dermatology ConferenceSurvey found that path to diagnosis for people with seborrheic dermatitis (average of 3.6 years) substantially longer than...
Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
05 oct. 2022 16h00 HE
|
Arcutis Biotherapeutics, Inc.
WESTLAKE VILLAGE, Calif., Oct. 05, 2022 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), an early commercial-stage biopharmaceutical company focused on developing meaningful...